Medicinal product name Lynparza
Pharmaceutical form Film-coated tablet
Strength 100 mg 
Information from the MAH on shortages No information on expected shortages
Availability of medicinal product
Product No.Package sizeWholesalers' stock state
EU/1/14/959/002 KZSN56 Is available
Legal status Rx Prescription (Pr.II onk. ķīm. ter.)
KZS NHS Reimbursed medicines
Summary of product characteristics, package leaflet and labeling text  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
Risk minimisation measuresVēstule veselības aprūpes speciālistam Vēstule veselības aprūpes speciālistam
Conclusion on the therapeutic and cost effectiveness of medicines May 7, 2020 C56
 May 30, 2023 C61
 Oct 23, 2023 C50
ATC code L01XK01 Antineoplastic agents

Medicinal products (1)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Is available (according to the information provided by wholesalers)
(15 containers)
Magnum Medical N56
(100 mg)
Al/Al blister 3412.63 
KZS*
EU/1/14/959/002  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
* Indication about medicine on the List of state reimbursed medicines is just informative. Source of the information is the National Health Service. For details please visit the NHS website.

Registration information

Marketing authorisation No. EU/1/14/959/002
Date of authorisation Dec 16, 2014
Marketing authorisation holder, country AstraZeneca AB, Sweden